• Join Today!

Become a member and connect with:

  • An Active Online Community
  • Articles and Advice on SCD
  • Help Understanding Clinical Trials
abstracts & posters

Sustainability of Hematological and Clinical Benefits to HU Administration in the Prevention of Sickle-Cell Vaso-Occlusive Crises in Routine Practice

key information

source: American Society of Hematology

year: 2018

authors: Ersi Voskaridou, Lena Oevermann, Corinne Armari-Alla, Uwe Kordes, Frédéric Galactéros, Malika Benkerrou, Isabelle Thuret, Dominique Steschenko


Hydroxyurea (HU) is approved in EU and USA for preventing vaso-occlusive crises (VOC) including acute chest syndromes (ACS) in adults, adolescents and children >=2 years with sickle-cell disease (SCD).

Further to the double blinded, randomized controlled Multicenter Study of Hydroxyurea administration (MSH) which provided the first data on clinical efficacy of HU (Charache 1995), a few follow-up studies suggested that long-term use of HU resulted in significant clinical benefit on patient outcome. This was reflected by lower mortality rates in HU-treated patients compared to conventionally treated patients (Steinberg 2003 & 2010, Voskaridou 2010, Lê 2015). Sustained hematological and clinical response after several years of follow-up at maximal tolerated dose was further shown in subsequent studies, especially the LaSHS study (Voskaridou 2010).

Based on these data, the ESCORT-HU (European Sickle Cell Disease COhoRT – HydroxyUrea) study was launched aiming in the establishment of the safety and the sustainability of hematological and clinical benefits to HU administration in the prevention of sickle-cell vaso-occlusive crises in routine practice. We hereby present preliminary results from a large cohort of patients enrolled in the study between January 2009 and June 2017.

Conclusion: In preliminary results from ESCORT-HU in 147 patients treated with HU showed sustained hematological and clinical response while MTD was not targeted, with differences between adults and children which may be attributed in part to reduced compliance in the latter group.

organization: Laikon General Hospital, Greece; Charité-Universitätsmedizin, Germany; Hopital de jour Hopital Couple Enfant CHU Grenoble, France; University Medical Center Eppendorf, Germany; Assistance Publique-Hôpitaux de Paris, France; CHU Henri Mondor, France; Robert Debré Hospital, France; Hôpital de la Timone, France; CHU de Nancy, France

DOI: 10.1182/blood-2018-99-116040

read more

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.